If you have been reading about bremelanotide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-09-05. Numbers and descriptions here follow the published literature rather than marketing material.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H68N14O10 | Free base; the drug product is formulated as an acetate salt |
| Molar mass | About 1025 g/mol | Calculated for the free base |
| Appearance | White to off-white lyophilized powder | Typical form of research-grade material |
| CAS Registry Number | 189691-06-3 | Common listing for the free base |
| Typical storage | -20 °C, desiccated, protected from light | Repeated freeze-thaw cycles are best avoided |
From a pharmacokinetic standpoint, the peptide is usually delivered by injection because oral bioavailability is very low; proteases in the digestive tract degrade it rapidly. After subcutaneous administration, plasma concentrations reach a peak within roughly one hour. Its elimination half-life is relatively short, with most reports placing it in the range of a few hours. Nasal formulations have also been examined, though absorption varies widely between individuals. Metabolism proceeds mainly through peptidase cleavage, and the resulting products are excreted by the kidneys.
PT-141 initiates cellular signaling by binding to specific subtypes within the melanocortin receptor family. These receptors belong to the G protein-coupled receptor superfamily, and activation raises intracellular cyclic adenosine monophosphate levels. This cascade ultimately influences neuronal circuits in the central nervous system that are associated with sexual desire and arousal. Research indicates the compound's action concentrates in hypothalamic regions rather than peripheral tissues, which helps explain some observed pharmacological features. The selectivity of receptor binding underlies its functional differences.
Compared with the related compound melanotan II, PT-141 shows markedly weaker activation of receptors tied to pigmentation. This difference stems from subtle structural variations that alter affinity distribution across receptor subtypes. Investigators propose that such selectivity produces a different side effect profile in specific applications. However, downstream consequences of prolonged receptor activation remain uncertain in the literature. Published studies do not fully agree on the duration of signaling pathway activity and the mechanisms of desensitization.
Reported pharmacodynamic effects include transient rises in blood pressure and heart rate, flushing, nausea and headache, appearing soon after dosing and resolving within hours. These responses were dose-related in early studies and shaped the label's cardiovascular cautions and blood pressure monitoring advice. Gastrointestinal upset is the most frequent reason cited for discontinuation in trials. Whether the vascular signal attenuates with repeated use is not settled. Central effects on desire are described as emerging over weeks rather than immediately, which points to a cumulative rather than acute process.
The compound binds several melanocortin receptor subtypes rather than a single target, with the strongest functional activity reported at MC4R and measurable activity at MC1R, MC3R and MC5R. MC4R populations are dense in hypothalamic nuclei that integrate energy balance, autonomic tone and reproductive behaviour, which is the anatomical basis for the proposed pro-desire effect. Because binding is not subtype-selective, pigmentary and vascular effects accompany central activity. Improving subtype selectivity is an active area of analogue design. Direct causal mapping from receptor occupancy to reported desire change in humans is not fully established.
==== Glutamate receptors ==== Ionotropic glutamate receptors can include NMDA, AMPA, and kainate receptors. These receptors are named after agonists that facilitate glutamate activity. NMDA receptors are notable for their excitatory mechanisms to affect neuronal plasticity in learning and memory, as well as neuropathologies such as stroke and epilepsy. NDMA receptors have multiple binding sites just like ionotropic GABA receptors and can be influenced by co-agonists such the glycine neurotransmitter or phencyclidine (PCP). The NMDA receptors carry a current by Ca2+ ions and can be blocked by extracellular Mg2+ ions depending on voltage and membrane potential. This Ca2+ influx is increased by excitatory postsynaptic potentials (EPSPs) produced by NMDA receptors, activating Ca2+-based signaling cascades (such as neurotransmitter release). AMPA generate shorter and larger excitatory postsynaptic currents than other ionotropic glutamate receptors.
Through its slope and y intercept we can obtain vmon and K, which are constants for each adsorbent–adsorbate pair at a given temperature. vmon is related to the number of adsorption sites through the ideal gas law. If we assume that the number of sites is just the whole area of the solid divided into the cross section of the adsorbate molecules, we can easily calculate the surface area of the adsorbent. The surface area of an adsorbent depends on its structure: the more pores it has, the greater the area, which has a big influence on reactions on surfaces. If more than one gas adsorbs on the surface, we define
Advances in Radical SAM Enzymology: New Structures and Mechanisms: Radical S-Adenosylmethionine Enzymes: Radical S-Adenosylmethionine (SAM) Enzymes in Cofactor Biosynthesis: A Treasure Trove of Complex Organic Radical Rearrangement Reactions: Molecular architectures and functions of radical enzymes and their (re)activating proteins: Radical SAM enzymes in RiPP biosynthesis. Radical SAM enzymes with a vitamin B12 (cobalamin)-binding domain.
On July 19, 2005, following the retirement of Associate Justice Sandra Day O'Connor on July 1, Bush nominated federal appellate judge John Roberts as her replacement; however, following the death of Chief Justice William Rehnquist on September 3, the still-pending nomination was withdrawn on September 5, with Bush instead nominating Roberts to be the next Chief Justice of the United States. He was confirmed by the Senate on September 29, 2005. On October 3, 2005, Bush nominated White House Counsel Harriet Miers to succeed O'Connor; however, Miers withdrew her nomination on October 27 after encountering significant opposition from both parties, who found her to be ill-prepared and uninformed on the law. Finally, on October 31, Bush nominated federal appellate judge Samuel Alito, who was confirmed by the Senate to replace O'Connor on January 31, 2006.
Sources: en.wikipedia.org
Treatment for thalassemia depends on the severity of the disease. People with thalassemia traits (thalassemia minor or non transfusion dependent thalassemia), may not require medical or follow-up care after the initial diagnosis is made. Occasionally transfusions may be necessary particularly around childbirth, surgery, or if other conditions provoke anemia. A folic acid supplement may also be recommended. For those with severe forms of thalassemia (thalassemia major, or transfusion-dependent thalassemia), the three principal treatments are red blood cell transfusions to relieve anemia, iron chelation to mitigate the side effects of transfusion, and folic acid supplementation to encourage the growth of new blood cells. Other forms of treatment available depending on individual circumstances.
First-generation NSAAs including bicalutamide, flutamide, and nilutamide are all synthetic, nonsteroidal anilide derivatives and structural analogues of each other. Bicalutamide is a diarylpropionamide while flutamide is a monoarylpropionamide and nilutamide is a hydantoin. Bicalutamide and flutamide, though not nilutamide, can also be classified as toluidides. All three of the compounds share a common 3-trifluoromethylaniline moiety. Bicalutamide is a modification of flutamide in which a 4-fluorophenylsulfonyl moiety has been added and the nitro group on the original phenyl ring has been replaced with a cyano group. Topilutamide, also known as fluridil, is another NSAA that is closely related structurally to the first-generation NSAAs, but, in contrast to them, is not used in the treatment of prostate cancer and is instead used exclusively as a topical antiandrogen in the treatment of pattern hair loss.
Noboa was inaugurated for his second term on 24 May 2025. Noboa said in March 2025 that he wanted American, European and Brazilian armies to join his war against criminal gangs. He added he would like President Donald Trump to designate Ecuadorean gangs as terrorist groups, as he has done for some Mexican and Venezuelan cartels. He thereafter started laying the groundwork for U.S. forces to arrive. He met Trump on 30 March 2025, with Trump agreeing to help. On 4 September, Noboa met with US Secretary of State Marco Rubio, who announced the planned expenditure of $20 million USD toward enhanced security cooperation with Ecuador. The United States also designated Los Choneros and Los Lobos as "foreign terrorist organizations." Noboa has cooperated with the US to expand the US military presence in Ecuador, allowing deployments at Manta Air Base, Guayaquil and San Cristóbal, Galapagos Islands under cooperation agreements, rather than bilateral treaties. In September 2025, Noboa's administration terminated a 15-year-old bilateral agreement with Venezuela that had provided a simplified visa and residency process. Noboa has significantly shifted Ecuador's migration policy toward stricter controls, with a particular focus on Venezuelan nationals.
The university consolidated its physicians' practice plans and transferred them, along with the university's hospital management functions, to UPMC, with UPMC providing ongoing financial support to the university and its academic missions in return. The result was a mutually exclusive partnership formalized by a series of interrelated agreements and mutual executive oversights, which shares numerous board members. This created a decision-making model in which UPMC oversees clinical activity, while the University of Pittsburgh guards academic priorities, particularly faculty-based research. Expansion of UPMC continued in 2001 as Children's Hospital of Pittsburgh began merging with UPMC. Since then, UPMC merged with Mercy Hospital in 2008; opened new Children's Hospital facilities in 2009; integrated Hamot Medical Center in Erie, Pennsylvania, in 2011, Altoona Regional Health System in Altoona, Pennsylvania, in 2013, and Jameson Health System in New Castle, Pennsylvania, in 2016; along with continued expansion of overseas operations and for-profit business ventures. In October 2016, Susquehanna Health, a four-hospital system in north central Pennsylvania, became the first domestic hospital outside Western Pennsylvania to join the UPMC system. UPMC Susquehanna merged with two additional community hospitals in October 2017. In December 2016, WCA Hospital of Jamestown, New York, became the first domestic hospital outside of Pennsylvania in the UPMC system.
The introduction or modification of a protecting group occasionally influences the reactivity of the whole molecule. For example, diagrammed below is an excerpt of the synthesis of an analogue of Mitomycin C by Danishefsky.
Sources: en.wikipedia.org
Glycine + tetrahydrofolate + NAD+ ⇌ CO2 + NH+4 + N5,N10-methylene tetrahydrofolate + NADH + H+ In the second pathway, glycine is degraded in two steps. The first step is the reverse of glycine biosynthesis from serine with serine hydroxymethyl transferase. Serine is then converted to pyruvate by serine dehydratase. In the third pathway of its degradation, glycine is converted to glyoxylate by D-amino acid oxidase. Glyoxylate is then oxidized by hepatic lactate dehydrogenase to oxalate in an NAD+-dependent reaction. The half-life of glycine and its elimination from the body varies significantly based on dose. In one study, the half-life varied between 0.5 and 4.0 hours.
== Other biology == Yeast grown under high concentrations of selenomethionine is able to convert selenomethionine into selenocysteine, much like methionine can be converted into cystine. Existence of selenocysteine is enough to trick the cystine-tRNA ligase into producing a tRNACys linked to selenocystine, resulting in the production of non-functional proteins and cytotoxicity.
When King Ferdinand II enacted a liberal constitution in January 1848 in the wake of popular demonstrations, many southern liberals were elected in the parliamentary elections. However, on 5 May 1848, in a coup d'état, he dissolved Parliament and bombed rebellious Naples, causing more than 1,000 deaths. Insurrectional committees arose in Calabria: the most organized were from Cosenza and Catanzaro, which raised arms, funds and volunteers to resist. Despite their efforts, divisions over how to conduct military operations compromised their efforts and the Calabrian insurgents were dispersed by the arrival of 5,000 Bourbon soldiers under Generals Nunziante and Busacca. Political repression followed the defeat, manifested in death sentences or life in prison (some in absentia) of the major leaders. This caused the final rift between the Bourbon monarchy and the liberal bourgeoisie, which soon joined the Italian unification cause. Counting on this connection. Giuseppe Garibaldi landed on the Calabrian coast, at Melito di Porto Salvo, on 19 August 1860, after conquering Sicily. The Calabrian insurgents led by Agostino Plutino from Reggio backed the Garibaldi volunteers. With their aid, at the 21 August Battle of Piazza Duomo, Garibaldi conquered Reggio Calabria. He disarmed as many as 12,000 of Colonel Vial's men at Soveria Mannelli. Garibaldi's army then marched on Naples, entering on September 6. The Battle of the Volturno (26 September-2 October 1860) averted the Bourbon reconquest of Naples.
==== Invasion preparedness ==== The Greenlandic government has asked citizens to prepare for a possible attack on Greenland by the United States, including by stockpiling supplies. According to a report by Danish broadcaster DR, published in March 2026, Danish forces also prepared defensive measures in early 2026, including the deployment of special forces units and the pre-positioning of medical supplies such as blood for potential casualties. Troops reportedly brought explosives intended to disable key airstrips in Nuuk and Kangerlussuaq to prevent American landings.
==== Longnose gar ==== Due to the heavily scaled skin of the Longnose gar, some of the mechanical properties differ from model of describing how eel skin adds movement. The scale row resists longitudinal forces, which unlike eel skin, makes the skin stiffer in the longitudinal direction, providing myomeres with leverage and anchorage for pulling tendons. At low curvatures, it appears that the dermis is slack on both the concave and convex sides of the body. When the dermis is placed in tension, and resistance to bending is developed, which is referred to as flexural stiffness of the fish skin. The flexural stiffness is a result of the two dimensional stiffness of fish with heavily scaled skin, such as the longnose gar. This mechanical property of fish skin is important to the way a fish swims, because this mechanical property passively stiffens the body, which would otherwise would have been done muscularly. The flexural stiffness of fish skin act in a manner similar to the mechanism by which eel skin acts as an external tendon, however in the case of fish skin, the flexural stiffness acts as a mechanism to decelerate body movement rather than to generate a propulsive force.
Sources: en.wikipedia.org
PT-141 is a research code for bremelanotide, a cyclic peptide that activates melanocortin receptors. It was developed for sexual dysfunction and later approved under a brand name as a subcutaneous injection. The same code is widely used by suppliers selling non-pharmaceutical material.
Both are synthetic melanocortin agonists and share a similar peptide backbone, but they are distinct molecules with different receptor profiles. Melanotan II was never approved as a medicine, whereas bremelanotide was. Findings about one compound should not be transferred to the other without direct evidence.
It is typically distributed as a lyophilized powder in sealed vials, sometimes with a separate solvent. Purity statements usually originate from the supplier rather than an independent laboratory. Storage recommendations vary between vendors, which makes comparison across sources difficult.
PT-141 was the development code used for bremelanotide during its preclinical and early clinical programme. The peptide is now generally referred to by its international nonproprietary name.